DK2297307T3 - Fremgangsmåder til fremstillingen af ips-celler under anvendelse af ikke-virale metoder - Google Patents

Fremgangsmåder til fremstillingen af ips-celler under anvendelse af ikke-virale metoder Download PDF

Info

Publication number
DK2297307T3
DK2297307T3 DK09759392.5T DK09759392T DK2297307T3 DK 2297307 T3 DK2297307 T3 DK 2297307T3 DK 09759392 T DK09759392 T DK 09759392T DK 2297307 T3 DK2297307 T3 DK 2297307T3
Authority
DK
Denmark
Prior art keywords
cells
cell
differentiation
ebna
vector
Prior art date
Application number
DK09759392.5T
Other languages
English (en)
Inventor
Amanda Mack
James Thomson
Original Assignee
Cellular Dynamics Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40977641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2297307(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellular Dynamics Int Inc filed Critical Cellular Dynamics Int Inc
Application granted granted Critical
Publication of DK2297307T3 publication Critical patent/DK2297307T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (37)

1. Fremgangsmåde til at tilvejebringe en cellepopulation med en ændret differentieringsstatus i forhold til en udgangscellepopulation og med celler der i det væsentlige er fri for programmeringsvektor-genetiske elementer, hvilken fremgangsmåde omfatter trinnene at: (a) opnå en udgangspopulation af celler med en første differentieringsstatus; (b) opnå én eller flere differentieringsprogrammeringsvektorer, hver vektor omfatter en replikationskilde og har én eller flere ekspressionskassetter der koder for én eller flere differentieringsprogrammeringsfaktorer der, i kombination, kan ændre differentieringsstatus af udgangscellepopulationen til en anden differentieringsstatus, hvor én eller flere af ekspressionskassetterne omfatter en nukleotidsekvens der koder for en trans-agerende faktor der binder til replikationskilden til at replikere en ekstra-kromosomal template, og/eller hvor cellerne af udgangspopulationen udtrykket en sådan trans-agerende faktor; (c) indføre differentieringsprogrammeringsvektor(er) i cellerne fra udgangspopulationen; (d) dyrke cellerne til at resultere i ekspression af den ene eller flere differentieringsprogrammeringsfaktorer sådan at træk der er konsistente med den anden differentieringsstatus opstår i mindst en del af cellerne i de dyrkede celler; og (e) yderligere dyrke cellerne med trækkene for et tilstrækkeligt antal generationer til at frembringe en målcellepopulation der omfatter celler med den anden differentieringsstatus men hvilke celler er i det væsentlige fri for programmeringsvektorgenetiske elementer.
2. Fremgangsmåden ifølge krav 1, endvidere omfattende et yderligere trin valgt fra gruppen bestående af at (a) udvælge celler fra de dyrkede celler i trin d) eller e), hvilke celler er i det væsentlige fri for differentierings-programmeringsvektorgenetiske elementer, og (b) udvælge celler fra de dyrkede celler i trin d) eller e), hvilke celler er i det væsentlige fri for en selektionsmarkør omfattet i differentieringsprogrammeringsvektoren.
3. Fremgangsmåden ifølge krav 2(b), hvor selektionsmarkøren er herpes simplex virus-thymidinkinase, en antibiotika-resistensfaktor, eller et fluorescerende protein.
4. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 3, hvor ændringen af differentierings-status er valgt fra gruppen bestående af reprogrammering, differentiering, og transdifferentiering.
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 4, hvor ændringen af differentierings-status er reprogrammering og hvor udgangscellerne er valgt fra gruppen bestående af (a) en somatisk celle og trækkene er defineret som én eller flere karakteristikker af embryoniske stamceller, og (b) en fibroblast, en keratinocyt, en hematopoietisk celle, en mesenchymal celle, en levercelle, en mavecelle, eller en β-celle.
6. Fremgangsmåden ifølge krav 5, endvidere omfattende et trin til differentiering af målcellepopulationen.
7. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 5, hvor ændringen af differentierings-status er reprogrammering og hvor differentieringsprogrammeringsfaktorerne yderligere er defineret som reprogrammeringsfaktorer omfattende Sox-2 og Oct-4.
8. Fremgangsmåden ifølge krav 7, hvor reprogrammeringsfaktorerne yderligere omfatter Nanog, Lin28, Klf4, eller c-Myc.
9. Fremgangsmåden ifølge krav 4, hvor ændringen af differentierings-status er differentiering og hvor udgangscellen er en embryonisk stamcelle, en induceret pluripotent stamcelle, en hæmatopoietisk stamcelle, en nervestamcelle, en mesenchymal stamcelle, en hæmatopoietisk progenitor, en endoderm progenitor, en pankreatisk progenitor, eller en endotelial progenitor.
10. Fremgangsmåden ifølge krav 4, hvor ændringen af differentierings-status er transdifferentiering og hvor den første og den anden differentierings-status er terminalt differentierede.
11. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 10, hvor replikationskilden er en replikationskilde af et lymfotropisk herpes virus, et adenovirus, SV40, et bovint Papillomavirus, eller en gær.
12. Fremgangsmåden ifølge krav 11, hvor replikationskilden er en replikationskilde af et lymfotropisk herpes virus og svarer til oriP af EBV.
13. Fremgangsmåden ifølge krav 11, hvor det lymfotropiske herpes virus er Epstein Barr virus (EBV), Kaposi's sarcom herpes virus (KSHV), Herpes virus saimiri (HS), eller Marek's sygdomsvirus (MDV).
14. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 13, hvor den trans-virkende faktor (a) svarer til EBNA-1 af EBV, (b) er et derivat af et vild-type protein svarende til EBNA-1 af EBV, derivat har en nedsat evne til at aktivere transskription fra en integreret template sammenlignet med vild-type EBNA-1, (c) er et derivat af et vild-type protein svarende til EBNA-1 af EBV, hvilket derivat aktiverer transskription ved niveauer på mindst 5% af det tilsvarende vild-type protein fra en ekstra-kromosomal template efter derivatet binder replikationskilden, eller (d) er et derivat af vild-typeprotein svarende til EBNA-1 af EBV, hvilket derivat har en deletion af grupper svarende til grupperne 65 til 89 af EBNA-1, og/eller en deletion af grupper svarende til grupperne 90 til 328 af EBNA-1.
15. Fremgangsmåden ifølge krav 14(b), eller 14(c), hvor derivatet der mangler sekvenser der er til stede i vild-type-EBNA-1 protein der aktiverer transskription fra en integreret template.
16. Fremgangsmåden ifølge krav 14(b), eller 14(c), hvor derivatet har en deletion af grupper svarende til grupperne 65 til 89 af EBNA-1 og/eller en deletion af grupper svarende til grupperne 90 til 328 af EBNA-1.
17. Fremgangsmåden ifølge krav 14(b), eller 14(c), hvor derivatet koder for et protein med mindst 80% aminosyresekvensidentitet til grupperne 1 til 40 og grupperne 328 til 641 af EBNA-1.
18. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 17, hvor ekspressionskassetter er operativt bundet til et transskriptionelt regulatorelement.
19. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 18, hvor flere gener effektivt udtrykkes under anvendelse af en enkelt promotor/forstærker til at transskribere en enkelt besked.
20. Fremgangsmåden ifølge krav 19, hvor flere åbne læserammer transskriberes sammen, hver separeret afen IRES, danner polycistroniske beskeder.
21. Differentierings-programmingsvektor omfattende en replikationskilde, og har én eller flere ekspressionskassetter der koder for en trans-virkende faktor der binder til replikationskilden til at replikere vektoren ekstra-kromosomalt; og én eller flere differentierings-programmeringsfaktorer.
22. Differentierings-programmeringsvektoren ifølge krav 21, hvor den transvirkende faktor er et derivat af et vild-type protein svarende til EBNA-1 af EBV, hvilket derivat aktiverer transskription på mindst 5% af det tilsvarende vild-type protein fra en ekstra-kromosomal template efter binding til replikationskilden og har en nedsat evne til at aktivere transskription fra en integreret template sammenlignet med vild-type EBNA-1.
23. Differentierings-programmeringsvektoren ifølge krav 22, hvor derivatet omfatter en første nukleotidsekvens der koder for grupperne 1 til 40 af den tilsvarende vild-type EBNA-1 og en anden nukleotidsekvens der koder for grupperne 328 til 641 af den tilsvarende vild-type EBNA-1.
24. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 23, hvor differentierings-programmeringsfaktorerne vælges fra gruppen bestående af Sox-2, Sox-7, Sox-17, Oct-4, Nanog, Lin-28, c-Myc, Klf4, Esrrb, EBF1, C/EBPa, C/ΕΒΡβ, Ngn3, Pdx og Mafa.
25. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 23, yderligere defineret som en reprogrammeringsvektor omfattende et Sox-familiemedlem og et Oct-familiemedlem.
26. Differentierings-programmeringsvektoren ifølge krav 25, hvor differentieringsprogrammeringsfaktorerne yderligere omfatter én eller flere valgt fra gruppen bestående af Nanog, Lin-28, Klf4, og c-Myc.
27. Differentierings-programmeringsvektoren ifølge krav 21, hvor differentieringsprogrammeringsvektoren mangler evnen til at blive integreret i et værtscellegenom.
28. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 27, hvor replikationskilden er en replikationskilde af et lymfotropisk herpes virus, et adenovirus, SV40, et bovint papillomavirus, eller en gær.
29. Differentierings-programmeringsvektoren ifølge krav 28, hvor replikationskilden er en replikationskilde af et lymfotropisk herpes virus og svarer til oriP af EBV.
30. Differentierings-programmeringsvektoren ifølge krav 28, hvor det lymfotropiske herpes virus er Epstein Barr virus (EBV), Kaposi's sarcom herpes virus (KSHV), Herpes virus saimiri (HS), eller Marek's sygdomsvirus (MDV).
31. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 30, hvor den trans-virkende faktor (a) svarer til EBNA-1 af EBV, (b) er et derivat af et vild-type protein svarende til EBNA-1 af EBV, hvilket derivat har en nedsat evne til at aktivere transskription fra en integreret template sammenlignet med vild-type EBNA-1, (c) er et derivat af et vild-type protein svarende til EBNA-1 af EBV, hvilket derivat aktiverer transskription ved niveauer på mindst 5% af det tilsvarende vild-type protein fra en ekstra-kromosomal template efter derivatet binder replikationskilden, eller (d) er et derivat af vild-typeprotein svarende til EBNA-1 af EBV, hvilket derivat har en deletion af grupper svarende til grupperne 65 til 89 af EBNA-1, og/eller en deletion af grupper svarende til grupperne 90 til 328 af EBNA-1.
32. Differentierings-programmeringsvektoren ifølge krav 31(b), 31(c), eller 22, hvor derivatet mangler sekvenser der er til stede i vild-type-EBNA-l-proteinet der aktiverer transskription fra en integreret template.
33. Differentierings-programmeringsvektoren ifølge krav 31(b), 31(c), eller 22, hvor derivatet har en deletion af grupper svarende til grupperne 65 til 89 af EBNA-1 og/eller en deletion af grupper svarende til grupperne 90 til 328 af EBNA-1.
34. Differentierings-programmeringsvektoren ifølge krav 31(b), 31(c), eller 22, hvor derivatet koder for et protein med mindst 80% aminosyresekvensidentitet til grupperne 1 til 40 og grupperne 328 til 641 af EBNA-1.
35. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 34, hvor ekspressionskassetter er operativt bundet til et transskriptionelt regulatorelement.
36. Differentierings-programmeringsvektoren ifølge et hvilket som helst af kravene 21 til 35, hvor flere gener effektivt udtrykkes under anvendelse af en enkelt promotor/forstærker til at transskribere en enkelt besked.
37. Differentierings-programmeringsvektoren ifølge krav 36, hvor flere åbne læserammer er transskriberet sammen, hver er separeret af en IRES, danner polycistroniske beskeder.
DK09759392.5T 2008-06-04 2009-06-04 Fremgangsmåder til fremstillingen af ips-celler under anvendelse af ikke-virale metoder DK2297307T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5885808P 2008-06-04 2008-06-04
US16058409P 2009-03-16 2009-03-16
PCT/US2009/046209 WO2009149233A1 (en) 2008-06-04 2009-06-04 Methods for the production of ips cells using non-viral approach

Publications (1)

Publication Number Publication Date
DK2297307T3 true DK2297307T3 (da) 2016-07-25

Family

ID=40977641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09759392.5T DK2297307T3 (da) 2008-06-04 2009-06-04 Fremgangsmåder til fremstillingen af ips-celler under anvendelse af ikke-virale metoder

Country Status (10)

Country Link
US (4) US8546140B2 (da)
EP (4) EP3447128A1 (da)
JP (5) JP2011522540A (da)
KR (2) KR101871192B1 (da)
AU (1) AU2009256202B2 (da)
CA (2) CA2954948A1 (da)
DK (1) DK2297307T3 (da)
ES (1) ES2587395T3 (da)
IL (1) IL209740A (da)
WO (1) WO2009149233A1 (da)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1970446E (pt) * 2005-12-13 2011-09-01 Univ Kyoto Factor de reprogramação nuclear
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
SG193653A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
KR101661940B1 (ko) * 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵 초기화 방법
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
CN105671065A (zh) * 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
EP3450545B1 (en) * 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
CN102369288A (zh) * 2008-11-14 2012-03-07 生命技术公司 用于工程化细胞的组合物和方法
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
US20100272695A1 (en) 2009-04-22 2010-10-28 Alan Agulnick Cell compositions derived from dedifferentiated reprogrammed cells
CN102459575A (zh) 2009-06-05 2012-05-16 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
AU2010279913B2 (en) 2009-08-07 2016-04-28 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011040887A1 (en) 2009-09-30 2011-04-07 Agency For Science, Technology And Research A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
EP2496689B1 (en) * 2009-11-04 2015-05-20 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
WO2011119942A1 (en) * 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
US20110312001A1 (en) 2010-06-15 2011-12-22 Emile Nuwaysir Compendium of ready-built stem cell models for interrogation of biological response
WO2011159684A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US9365826B2 (en) 2010-06-18 2016-06-14 Cellular Dynamics International, Inc. Cardiomyocyte medium with dialyzed serum
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
US20130309209A1 (en) * 2010-10-22 2013-11-21 Center For Regenerative Medicine Of Barcelona Formation of hematopoietic progenitor cells from mesenchymal stem cells
JP6005666B2 (ja) 2011-02-08 2016-10-12 セルラー ダイナミクス インターナショナル， インコーポレイテッド プログラミングによる造血前駆細胞の生産
US9228204B2 (en) 2011-02-14 2016-01-05 University Of Utah Research Foundation Constructs for making induced pluripotent stem cells
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
WO2013009825A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
WO2013022022A1 (ja) * 2011-08-08 2013-02-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CA2852244C (en) 2011-10-17 2023-10-17 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013086008A1 (en) 2011-12-05 2013-06-13 Factor Bioscience Inc. Methods and products for transfecting cells
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
WO2013137491A1 (ja) 2012-03-15 2013-09-19 国立大学法人京都大学 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
US20150064734A1 (en) 2012-03-21 2015-03-05 Kyoto University Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
JP6112733B2 (ja) 2012-04-06 2017-04-12 国立大学法人京都大学 エリスロポエチン産生細胞の誘導方法
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
US9416705B2 (en) 2012-04-27 2016-08-16 Hino Motors, Ltd. Burner and filter renewal device
AU2013264708B2 (en) 2012-05-23 2019-03-07 Kyoto University Highly efficient method for establishing artificial pluripotent stem cell
US9175263B2 (en) 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
US9382531B2 (en) 2012-10-22 2016-07-05 Wisconsin Alumni Research Foundation Induction of hemogenic endothelium from pluripotent stem cells
EP3786298A1 (en) 2012-11-01 2021-03-03 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
AU2014248167B2 (en) 2013-04-03 2019-10-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
WO2014170549A1 (en) * 2013-04-16 2014-10-23 Glykos Finland Oy A method for generating induced pluripotent stem cells
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
EP3011014A4 (en) 2013-06-14 2017-02-08 The University of Queensland Renal progenitor cells
CN103333918B (zh) * 2013-06-19 2015-12-02 中山大学 一种提高猪克隆胚胎体外发育效率的方法
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
US9988605B2 (en) 2013-12-11 2018-06-05 Korea Advanced Institute Of Science And Technology Method for preparing endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells
EP3099801B1 (en) 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
EP3134515B1 (en) 2014-04-24 2019-03-27 Board of Regents, The University of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3584312A1 (en) * 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus e4orf1, and methods of making and using the same
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CA2957801C (en) 2014-08-19 2022-08-30 Cellular Dynamics International, Inc. Neural networks formed from cells derived from pluripotent stem cells
WO2016061071A1 (en) 2014-10-14 2016-04-21 Cellular Dynamics International, Inc. Generation of keratinocytes from pluripotent stem cells and mantenance of keratinocyte cultures
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
LT3347457T (lt) 2015-09-08 2022-02-10 FUJIFILM Cellular Dynamics, Inc. Tinklainės pigmento epitelio ląstelių, kilusių iš kamieninių ląstelių, valymas macs metodu
ES2970537T3 (es) 2015-09-08 2024-05-29 Us Health Método para la diferenciación reproducible de células epiteliales del pigmento retiniano de calidad clínica
CN108350429B (zh) 2015-10-20 2022-02-25 富士胶片细胞动力公司 用于将多能干细胞定向分化为免疫细胞的方法
JP2019500910A (ja) * 2016-01-12 2019-01-17 ロンザ ウォカーズビル インコーポレーティッド ベクターを含まない人工多能性幹細胞を作製するための方法およびベクター
WO2017196175A1 (en) 2016-05-12 2017-11-16 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
CN109844102B (zh) 2016-08-16 2023-11-10 富士胶片细胞动力股份有限公司 分化多能细胞的方法
CA3033788A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018064323A1 (en) 2016-09-28 2018-04-05 Organovo, Inc. Use of engineered renal tissues in assays
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
AU2017359330B2 (en) 2016-11-09 2022-03-10 The United States Of America, As Represented By The Secretary Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
CN110891967A (zh) 2017-04-18 2020-03-17 富士胶片细胞动力公司 抗原特异性免疫效应细胞
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
EP3692139A1 (en) 2017-10-03 2020-08-12 Wallkill Biopharma, Inc. Treating diabetes with genetically modified beta cells
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
AU2019256723A1 (en) 2018-04-20 2020-11-05 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
KR20210095885A (ko) 2018-11-19 2021-08-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 생분해성 조직 대체 임플란트 및 그의 용도
EP3887518A2 (en) 2018-11-28 2021-10-06 Board of Regents, The University of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4074321A4 (en) 2019-12-12 2024-01-03 Univ Chiba Nat Univ Corp FREEZE DRIED PREPARATION CONTAINING MEGAKARYOCYTES AND PLATELETS
EP4157294A1 (en) 2020-05-29 2023-04-05 FUJIFILM Cellular Dynamics, Inc. Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
US20230212509A1 (en) 2020-05-29 2023-07-06 FUJIFILM Cellular Dynamics, Inc. Bilayer of retinal pigmented epithelium and photoreceptors and use thereof
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
JPWO2022075384A1 (da) 2020-10-07 2022-04-14
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4255922A1 (en) 2020-12-03 2023-10-11 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022204567A1 (en) * 2021-03-25 2022-09-29 Bluerock Therapeutics Lp Methods for obtaining induced pluripotent stem cells
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
JP2024514522A (ja) 2021-04-07 2024-04-02 センチュリー セラピューティクス，インコーポレイテッド 遺伝子導入ベクターおよび細胞を操作する方法
JP2024513454A (ja) 2021-04-07 2024-03-25 センチュリー セラピューティクス，インコーポレイテッド キメラ抗原受容体細胞のための人工細胞死／リポーター系ポリペプチドの組合せおよびその使用
KR20230165846A (ko) 2021-04-07 2023-12-05 후지필름 셀룰러 다이내믹스, 인코포레이티드 도파민성 전구세포 및 사용 방법
CN117441010A (zh) 2021-04-07 2024-01-23 世纪治疗股份有限公司 从诱导多能干细胞产生α-βT细胞的组合物和方法
CN117881777A (zh) 2021-05-26 2024-04-12 富士胶片细胞动力公司 防止多能干细胞中基因快速沉默的方法
JP2024520424A (ja) 2021-05-28 2024-05-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 黄斑、中心および末梢網膜色素上皮細胞を生成する方法
WO2022251477A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
AU2022343749A1 (en) 2021-09-13 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
US20240034992A1 (en) * 2021-10-29 2024-02-01 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
WO2023196577A1 (en) * 2022-04-08 2023-10-12 New York Stem Cell Foundation, Inc. Methods for production of ipscs
WO2023215826A1 (en) 2022-05-04 2023-11-09 Century Therapeutics, Inc. Cells engineered with an hla-e and hla-g transgene
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023247532A1 (en) 2022-06-21 2023-12-28 Institut National de la Santé et de la Recherche Médicale A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
EP0604662B1 (en) 1992-07-07 2008-06-18 Japan Tobacco Inc. Method of transforming monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
DE19635568C1 (de) * 1996-09-02 1998-03-26 Gsf Forschungszentrum Umwelt Vektorsysteme zur konditionalen Genexpression
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
US20040199935A1 (en) 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
AU6842001A (en) 2000-06-15 2001-12-24 Tanja Dominko Pluripotent mammalian cells
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20020136709A1 (en) 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US20030044976A1 (en) 2001-08-27 2003-03-06 Advanced Cell Technology De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JP2004248505A (ja) * 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
ITMI20012110A1 (it) 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
WO2003056019A1 (en) * 2001-12-24 2003-07-10 Es Cell International Pte Ltd Method of transducing es cells
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0206357D0 (en) * 2002-03-18 2002-05-01 Univ Bath Cells
US20060128018A1 (en) 2003-02-07 2006-06-15 Zwaka Thomas P Directed genetic modifications of human stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
US7465580B2 (en) * 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
CA2579652A1 (en) 2004-09-08 2006-03-16 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
PT1970446E (pt) 2005-12-13 2011-09-01 Univ Kyoto Factor de reprogramação nuclear
JP4803584B2 (ja) * 2006-02-08 2011-10-26 独立行政法人産業技術総合研究所 脂質生産性の高い形質転換微生物
EP2048229B1 (en) 2006-07-07 2016-02-17 Kyowa Hakko Kirin Co., Ltd. Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector
US20100137202A1 (en) 2006-07-19 2010-06-03 University Of Florida Research Foundation Compositions for reprogramming a cell and uses therefor
US20110318792A1 (en) 2006-08-15 2011-12-29 Ishihara Sangyo Kaisha, Ltd. Novel method for utilization of microbial mutant
JP2008067693A (ja) * 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
US20100069251A1 (en) 2006-09-15 2010-03-18 Children's Medical Center Corporation Methods for producing embryonic stem cells from parthenogenetic embryos
SG193653A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
WO2008150814A2 (en) 2007-05-29 2008-12-11 Reid Christopher B Methods for production and uses of multipotent cell populations
US20100184051A1 (en) * 2007-05-30 2010-07-22 The General Hospital Corporation Methods of generating pluripotent cells from somatic cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
CN101855338B (zh) 2007-08-31 2013-07-17 怀特黑德生物医学研究所 在程序重排体细胞中的wnt途径刺激
CN101617043B (zh) 2007-10-31 2014-03-12 国立大学法人京都大学 核重编程方法
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
US9005966B2 (en) 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) * 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
US9206439B2 (en) 2008-01-14 2015-12-08 Wisconsin Alumni Research Foundation Efficient oriP/EBNA-1 plasmid vector
WO2009092042A1 (en) 2008-01-18 2009-07-23 Nevada Cancer Institute Reprogramming of differentiated progenitor or somatic cells using homologous recombination
EP2268796A1 (en) * 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
KR101661940B1 (ko) 2008-05-02 2016-10-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵 초기화 방법
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
WO2009157201A1 (en) 2008-06-26 2009-12-30 Osaka University Method and kit for preparing ips cells
WO2010012077A1 (en) 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
WO2010028019A2 (en) * 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
EP3450545B1 (en) 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming

Also Published As

Publication number Publication date
EP3447128A1 (en) 2019-02-27
JP2014209912A (ja) 2014-11-13
KR20110036548A (ko) 2011-04-07
EP3112456A1 (en) 2017-01-04
JP2011522540A (ja) 2011-08-04
CA2726990A1 (en) 2009-12-10
US20140038293A1 (en) 2014-02-06
AU2009256202B2 (en) 2014-07-03
US9328332B2 (en) 2016-05-03
CA2954948A1 (en) 2009-12-10
KR20160025045A (ko) 2016-03-07
WO2009149233A1 (en) 2009-12-10
US20180340150A1 (en) 2018-11-29
EP2297307A1 (en) 2011-03-23
KR101648019B1 (ko) 2016-08-16
JP2020115881A (ja) 2020-08-06
JP2018007667A (ja) 2018-01-18
KR101871192B1 (ko) 2018-06-27
US20130189778A1 (en) 2013-07-25
EP3279314A1 (en) 2018-02-07
IL209740A (en) 2014-01-30
AU2009256202A1 (en) 2009-12-10
US8546140B2 (en) 2013-10-01
US20100003757A1 (en) 2010-01-07
ES2587395T3 (es) 2016-10-24
US9644184B2 (en) 2017-05-09
JP2018019684A (ja) 2018-02-08
IL209740A0 (en) 2011-02-28
EP2297307B1 (en) 2016-06-01
CA2726990C (en) 2020-09-08

Similar Documents

Publication Publication Date Title
DK2297307T3 (da) Fremgangsmåder til fremstillingen af ips-celler under anvendelse af ikke-virale metoder
JP2011522540A5 (da)
AU2009282133B2 (en) Methods for the Production of IPS Cells
US20170226483A1 (en) Methods and Vectors to Produce Vector Free Induced Pluripotent Stem Cells
US20110061118A1 (en) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
US20110003365A1 (en) Method of preparing induced pluripotent stem cells deprived of reprogramming gene
EP2103685A1 (en) Vectors and methods for generating vector-free induced pluripotent stem (iPS) cells using site-specific recombination
WO2011005580A2 (en) Adult animals generated from induced pluripotent cells